ManagedCareCGM

This site is intended for managed care professionals in the U.S.

This site is intended for managed care professionals in the U.S.

Professionals in Canada should visit CanadaCGM.com

Continuous Glucose Monitoring

Education for Managed Care, Pharmacy, and Payer Professionals

Interviews

A CGM Expert Interview With Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)

 

As part of a new series of video resources hosted on ManagedCareCGM.com, Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP), offers her insights on progressive approaches to diabetes coverage and management. She shares HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level and enhanced access among patients with diabetes who are prescribed any insulin or ≥3 non-insulin medications. Findings from the MOBILE study—on which Ms. Kruger served as an investigator/author—are also detailed, including the benefits associated with real-time CGM (rtCGM) in type 2 diabetes (T2D) for improving glycemic control and meeting quality measures; these findings were particularly noteworthy considering a racially and ethnically diverse study population representing traditionally underserved demographics of patients. A post hoc analysis from MOBILE is likewise discussed, along with its implications for using rtCGM to improve T2D management among Medicare beneficiaries. 

 

Expert Interview with Jeffrey D. Dunn, PharmD, MBA on Appropriate Utilization Management Strategies for Continuous Glucose Monitoring 


 

Expert Interview Series with Professor Thomas Danne

Expert: Thomas Danne, MD, Professor of Pediatrics, Children’s Hospital Auf der Bult, Hanover, Germany

Part 1 – Glycemic Control: Opportunities and Challenges

References:
International Consensus on Use of Continuous Glucose Monitoring
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range 

Part 2 – Time in Range and Reduction in Diabetes-Related Complications

References:
Going Beyond A1c – One Outcome Can’t Do It All
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Continuous Glucose Monitoring in Adults with Type 1 Diabetes: Real-World Data from the German/Austrian Prospective Diabetes Follow-Up Registry

Part 3 – Virtual Care and the Future of CGM


References:
Acceptability and Utilization of Newer Technologies and Effects on Glycemic Control in Type 2 Diabetes: Lessons Learned from Lockdown
Blood Glucose Control During Lockdown for COVID-19: CGM Metrics in Italian Adults With Type 1 Diabetes
Personal Experience With COVID-19 and Diabetes in the South of France: Technology Facilitates the Management of Diabetes in Disruptive Times

 

PHP Code Snippets Powered By : XYZScripts.com